A Randomized, Open-Label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05) (Gilead Sciences GS-US-595-6184)
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which includes either pembrolizumab or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after surgery and pre-surgical treatment.
Contact
Clinical Trials Office at [email protected] or (203) 358-8879.
Principal Investigator(s)
Jamie Stratton, MD
Sponsor(s)
Gilead Sciences
Location
Bennett Cancer Center
One Hospital Plaza
Stamford, CT 06902
Main: 203-358-8879
Stamford, CT 06902
Main: 203-358-8879